Correction: An MDM2 degrader for treatment of acute leukemias

被引：0
|
作者：
Bridget K. Marcellino
Xiaobao Yang
H. Ümit Kaniskan
Claudia Brady
He Chen
Karie Chen
Xing Qiu
Cara Clementelli
Lauren Herschbein
Zhijun Li
Sebastian Elghaity-Beckley
Joann Arandela
Brianna Kelly
Ronald Hoffman
Jing Liu
Yue Xiong
Jian Jin
Alan H. Shih
机构：
[1] Icahn School of Medicine at Mount Sinai (ISMMS),Department of Medicine, Division of Hematology Oncology and Tisch Cancer Institute (TCI)
[2] Tisch Cancer Institute (TCI) Icahn School of Medicine at Mount Sinai (ISMMS),Mount Sinai Center for Therapeutics Discovery, Departments of Pharmacological Sciences, Oncological Sciences, and Neuroscience
[3] New York,undefined
[4] University of North Carolina at Chapel Hill,undefined
[5] Cullgen Inc.,undefined
来源：
Leukemia | 2023年 / 37卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1764 / 1765
页数：1
相关论文
共 50 条
  • [21] Binding of an inhibitor of the p53/MDM2 interaction to MDM2
    Duncan, SJ
    Cooper, MA
    Williams, DH
    CHEMICAL COMMUNICATIONS, 2003, (03) : 316 - 317
  • [22] MDM2 function
    Lozano, G
    Luna, RMD
    BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 1998, 1377 (02): : M55 - M59
  • [23] MDM2 Inhibition as a New Treatment Approach in AML
    Konopleva, Marina
    ANNALS OF HEMATOLOGY, 2019, 98 : S74 - S75
  • [24] Targeting MDM2 for Treatment of Adenoid Cystic Carcinoma
    Warner, Kristy A.
    Noer, Felipe
    Acasigua, Gerson A.
    Martins, Manoela D.
    Zhang, Zhaocheng
    McLean, Scott A.
    Spector, Matthew E.
    Chepeha, Douglas B.
    Helman, Joseph
    Wick, Michael J.
    Moskaluk, Christopher A.
    Castilho, Rogerio M.
    Pearson, Alexander T.
    Wang, Shaomeng
    Noer, Jacques E.
    CLINICAL CANCER RESEARCH, 2016, 22 (14) : 3550 - 3559
  • [25] MDM2 GENE ALTERATIONS AND MDM2 PROTEIN EXPRESSION IN BREAST CARCINOMAS
    MARCHETTI, A
    BUTTITTA, F
    GIRLANDO, S
    DALLAPALMA, P
    PELLEGRINI, S
    FINA, P
    DOGLIONI, C
    BEVILACQUA, G
    BARBARESCHI, M
    JOURNAL OF PATHOLOGY, 1995, 175 (01): : 31 - 38
  • [26] MDM2 gene amplification as a predictive biomarker for the MDM2 inhibitor milademetan
    Tirunagaru, Vijaya G.
    Gounder, Mrinal M.
    Kumar, Prasanna R.
    Hong, David S.
    Doebele, Robert C.
    MOLECULAR CANCER THERAPEUTICS, 2021, 20 (12)
  • [27] MDM2 and PARP as therapeutic targets in acute myeloid leukemia
    Zeuner, S.
    Shah, V
    Haehnel, P. S.
    Szybinski, J.
    Strand, D.
    Theobald, M.
    Kuehn, M. W. M.
    Kindler, T.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 77 - 78
  • [28] A TSG101/MDM2 regulatory loop modulates MDM2 degradation and MDM2/p53 feedback control
    Li, LM
    Liao, J
    Ruland, J
    Mak, TW
    Cohen, SN
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (04) : 1619 - 1624
  • [29] The contribution of the acidic domain of MDM2 to p53 and MDM2 stability
    Manuela Argentini
    Nadia Barboule
    Bohdan Wasylyk
    Oncogene, 2001, 20 : 1267 - 1275
  • [30] Inhibition of p53-MDM2 interaction by small-molecule antagonist of MDM2 effectively induces apoptosis in leukemias.
    Kojima, K
    Konopleva, M
    Shikami, M
    Cabreira-Hansen, M
    Jackson, CE
    Shpall, EJ
    Kornblau, SM
    Vassilev, LT
    Andreeff, M
    BLOOD, 2004, 104 (11) : 695A - 695A
12345